BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12151972)

  • 1. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
    Lynch JW; Hei DL; Braylan RC; Rimzsa LM; Staab EV; Bewsher CJ; Mendenhall NP; Hudson JK
    Am J Clin Oncol; 2002 Aug; 25(4):391-7. PubMed ID: 12151972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
    Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
    J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
    Enschede SH; Porter C; Venugopal P; Gregory SA
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
    Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R
    J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Magagnoli M; Rondelli D; de Vivo A; Benni M; Zamagni E; Cavo M; Tura S
    Eur J Haematol; 1997 Aug; 59(2):82-8. PubMed ID: 9293855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R; van de Loo J
    Eur J Cancer; 1991; 27 Suppl 4():S37-9. PubMed ID: 1799474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.
    Smalley RV; Weller E; Hawkins MJ; Oken MM; O'Connell MJ; Haase-Statz S; Borden EC
    Leukemia; 2001 Jul; 15(7):1118-22. PubMed ID: 11455982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
    Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
    J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Fountzilas G; Papageorgiou E; Kiamouris C; Mantzios G; Anagnostopoulos A; Nicolaides C; Economopoulos T;
    Leuk Lymphoma; 2002 Jan; 43(1):111-4. PubMed ID: 11908713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
    Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A
    Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
    Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
    J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
    Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
    Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.
    Enschede SH; Shahidi H; Venugopal P; Riley MB; Huang R; Jajeh A; Preisler HD; Gregory SA
    Leuk Lymphoma; 2001 Jan; 40(3-4):325-34. PubMed ID: 11426554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
    Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S;
    Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
    Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
    J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.